PI3Kα-RAS | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

8,172 results for “PI3Kα-RAS”

Trials

View all 4137 →

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors

220 participants · First posted Feb 3, 2025

Apremilast for RAS

15 participants · First posted Oct 1, 2018

CAMS-RAS: for Suicide Prevention

26 participants · First posted Mar 7, 2017

Drugs

View all 547 →

RAS-F3

RAS-001

RAS-111

Organizations

View all 220 →

Erasca

United States

Revolution Medicines, Inc.

United States

Ikena Oncology

United States

News

View all 3268 →

Frontier Medicines Unveils FMC-242, Novel PI3Kα/RAS Inhibitor Targeting Cancer's Most Common Genetic Drivers

BBOT's BBO-10203 Shows Broad Anti-Tumor Activity in Science Publication, Advances to Phase 1 Trial

BBOT Advances Triple KRAS-PI3Kα Pipeline with Dual Combination Dosing, Reports $344M Cash Runway into 2028

Page 1 of 818